Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Encorafenib (Braftovi®)	TA668 - Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Encorafenib with binimetinib	TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Enoxaparin Injection		For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA. However, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain red (ESCAs to be developed).
Entrectinib	TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide capsules	TA377 - Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide capsules	TA316 - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer	For hospital use only
Eosin solution 2% w/v		Unlicensed special
Ephedrine injection		Hospital use only
Epirubicin injection		For hospital use only
Epirubilin solution for injection	TA250 - Eribulin for the treatment of locally advanced or metastatic breast cancer TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.